{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.03","upperLimit":"63.78","value":"51.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"ORR is defined as the percent of participants with best overall response of partial response (PR) or better. Response is determined per IMWG uniform criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received treatment with Elotuzumab in combination with Pomalidomide and low-dose Dexamethasone in a 28 day cycle.","id":"OG000","title":"EPd Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to study completion date (up to approximately 50 months)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}